Elekta, SE0000163628

Elekta updates dividend plans, shares on Nasdaq Stockholm in focus

30.06.2026 - 13:24:43 | ad-hoc-news.de

Elekta outlines its latest shareholder distribution and financial framework while analysts reassess the Swedish medtech group against peers in radiation therapy and oncology software.

Elekta, SE0000163628
Elekta, SE0000163628

By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-30, 13:24.

Elekta (SE0000163628) remains a key medtech listing on Nasdaq Stockholm, with investors tracking its capital allocation and dividend framework after recent board communications and the latest annual general meeting in Sweden.Elekta investor relations overview

Analyst views on Elekta

Sell-side coverage on Elekta centers on its earnings trajectory, margin profile and cash generation, with several European houses publishing updated views in the last months to reflect the latest full-year report and guidance.MarketScreener consensus on Elekta

Consensus data compiled by MarketScreener indicates a mixed recommendation structure on the Elekta stock, with ratings ranging from Buy to Hold and Sell, as analysts balance the recurring software revenues against hardware cycle dynamics and hospital budget constraints.Consensus earnings estimates

How Elekta compares in medtech

In the radiation therapy and oncology systems segment, Elekta is frequently compared with peers such as Varian (part of Siemens Healthineers) and Accuray, with investors focusing on installed base, service revenues and innovation in treatment planning and delivery.Reuters coverage on Siemens Healthineers

Analysts highlight Elekta's exposure to emerging markets, where radiotherapy capacity remains structurally undersupplied, and note that order intake and backlog trends are critical metrics for assessing medium-term growth and margin resilience in the global oncology equipment market.Bloomberg profile of Elekta on Nasdaq Stockholm

Go deeper

Background and price data on Elekta

Historic earnings, consensus trends and past ad hoc releases on the Elekta shares are collected in the ad-hoc-news topic section and the company’s investor relations portal.

How Elekta makes its money

Elekta generates revenues from a portfolio of radiotherapy solutions, oncology information systems and related services, including its flagship linear accelerators and the Unity MR-Linac platform, which combine magnetic resonance imaging with precision radiation delivery for cancer treatment.Elekta Unity product page

Where the Elekta shares trade

The Elekta shares (SE0000163628) trade on Nasdaq Stockholm, with the latest verifiable quote and market capitalization available via the Swedish exchange and major financial data providers; current intraday price data should be obtained from a live quote service.

Key data on the Elekta shares

  • Company: Elekta AB
  • ISIN: SE0000163628
  • WKN: 894804
  • Ticker: EKTAB
  • Trading venue: Nasdaq Stockholm
  • Price (as of 2026-06-30, 11:20): not live-verifiable SEK
  • Market cap: not live-verifiable SEK (as of 2026-06-30)
  • Sector / industry: Health Care Equipment & Supplies
  • Index membership: Stockholm benchmark and sector indices
  • Next earnings date: not officially scheduled

More on the Elekta shares in social media

This article is for informational purposes only and does not constitute investment advice, a recommendation to buy or sell any security, or a solicitation of any kind. All data and assessments are based on sources believed to be reliable at the time of publication but may change without notice.

en | SE0000163628 | ELEKTA | boerse | 69660317 | bgmi